Navigation Links
Gulf Breeze Recovery Comments on New Opioid Antidote Alternative to Narcan
Date:4/17/2019

With Fentanyl overdose deaths continuing to claim lives and keeping the opioid crisis in the headlines, scientists are working to curb the death toll by looking for an alternative to naloxone. Researchers are presenting their findings to the American Chemical Society Spring 2019 National Meeting & Exposition this week.

Naloxone (often known by the name brand Narcan) has been utilized increasingly since the opioid crisis began to reverse overdoses from heroin and other opioids. The problem with Fentanyl is that it is a long-acting opioid. It can be absorbed in fat tissue, which does not allow it to be metabolized right away. The body slowly releases the drug from the fat tissue over the course of several hours. Naloxone, which only acts in the body for about 30 minutes, does not last for long enough to fully counter Fentanyl. Often, for Fentanyl overdoses, multiple naloxone injections are needed over a period of time to reverse the overdose. Sometimes, tragically, even multiple doses are not enough.

To overcome this challenge, researchers are developing a delivery system in which a dose of an opioid antagonist will be delivered over the course of 24 hours.

"Ultimately, we hope to develop a therapeutic intervention for fentanyl overdose that can be used in the field, perhaps supplanting short-acting naloxone as an overdose antidote of choice," says Saadyah Averick, Ph.D., a scientist at Allegheny Health Network Research Institute. "We anticipate that this drug delivery system will also be effective for other non-fentanyl opioids."

Barnett Gilmer, owner and CEO of Gulf Breeze Recovery, a non-12 step substance abuse treatment center in Florida, weighs in on the new developments.

“In the last couple of years, we have really seen an increase in people who are entering treatment for Fentanyl addiction. For those who have gotten clean for a period of time and subsequently relapsed, Fentanyl can be particularly deadly. The effects of a Fentanyl overdose are often so difficult to reverse that the consequences can be fatal. Unfortunately, too many people don’t get another chance to find recovery. Here at Gulf Breeze Recovery, we actually specialize in helping those who are struggling with chronic relapse. An opioid antidote that is effective for Fentanyl would mean that more people struggling with addiction will get the chance to actually try something different. It would mean another chance to save a life.”

About Gulf Breeze Recovery: Gulf Breeze Recovery is changing the future of addiction treatment with the THRIVE® program focused on overcoming chronic relapse. Gulf Breeze Recovery’s THRIVE® program is designed for those who are looking for a drug and alcohol treatment program to produce a different and positive result. This non-12 step program allows you to drive beyond your addictions and promotes a new outlook on life. For more information about our program or to speak with an Addiction’s expert, please call 855-973-3551 or contact us.

Read the full story at https://www.prweb.com/releases/gulf_breeze_recovery_comments_on_new_opioid_antidote_alternative_to_narcan/prweb16223137.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. Gulf Breeze Recovery on Reduction in Opioid Deaths and an Increase in Hope
2. Gulf Breeze Recovery Applauds Google's Decision on Deceptive Drug Rehab Advertising
3. Power Breezer Debuts New Ductwork Extension at the National Safety Council Congress and Expo
4. Urbini Breezes Through Summer with New Jogging Stroller
5. Inspiring New Book ‘My Recovery from Alcohol and Drugs” is Released
6. Asana Recovery Announces New Healthcare Scholarship Now Open for Applications
7. Siberian Pine Nut Oil for Postoperative Recovery
8. New Vitae Wellness and Recovery Celebrates 35th Anniversary
9. AIA Offers Resources for Recovery from California Wildfires
10. Baymark Health Services Opens Applegate Recovery in Baton Rouge
11. Broken Arrow, OK, Signs the First Disaster Recovery Agreement with OMSC and IBTS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... LOS ANGELES (PRWEB) , ... August 16, 2019 ... ... representing the Los Angeles market, has joined the esteemed Haute Beauty Network. , ... Haute Living is privileged to present Dr. Arnaoutakis as a hair restoration expert ...
(Date:8/15/2019)... ... ... students either starting college for the first time, and returning to school, the number of ... “there are about 20 million new cases of STDs each year in the United States. ... Young people are at greater risk of getting an STD.” To that end, myLAB ...
(Date:8/14/2019)... N.C. (PRWEB) , ... August 14, 2019 , ... Teguar ... private companies in America. This list has long-been established as a mark of success ... including LinkedIn, Dell, and Oracle. Teguar made the list in 2015, 2016 and 2017. ...
(Date:8/14/2019)... ... August 15, 2019 , ... R3 Stem Cell announced ... Stem Cell International is offering regenerative procedures with mesenchymal stem cells performed by ... costs only $2950, which includes a complete IV therapy or two joint injections. ...
(Date:8/14/2019)... , ... August 13, 2019 , ... In a recent ... purpose of doubt in your belief systems. , “Doubt can obliterate your old beliefs,” ... the path to examining them to expand your understanding and your awareness. Trust that ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... ... 16, 2019 , ... Sacramento-based physician recruiting firm, MDstaffers , was named ... magazine. MDstaffers three-year growth of more than 5,600 percent made it the 6th fastest ... company had it competed in this category. This news comes nine-years after MDstaffers was ...
(Date:8/16/2019)... ... August 16, 2019 , ... Today, ... (Wilkins) Rolle, PharmD, PhD, has joined the company as a Government Affairs and ... private sectors and industry standards organizations to advance use of health IT for ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT ... announced it has successfully completed enrollment of 690 patients for a phase III ... ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, ...
Breaking Medicine Technology: